Becker's Healthcare January 14, 2025
The Federal Trade Commission released a second interim report showing that the three largest pharmacy benefit managers — CVS Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx — marked up specialty generic drug prices, generating over $7.3 billion in excessive revenues from 2017 to 2022.
The report focuses on price increases for critical medications, including those used to treat HIV, cancer and other critical conditions. The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent, passing costs onto patients, employers and health plans, according to a Jan. 14 news release from the agency.
The FTC’s findings also indicate that these PBMs engaged in spread pricing, earning an estimated $1.4 billion...
Today's Sponsors
Today's Sponsor